Valued at USD 4.61 billion in 2023, the Vaccine Contract Manufacturing Market is projected to reach USD 5.16 billion in 2024 and USD 13.16 billion by 2032, growing at a CAGR of 12.4% during the forecast period 2024–2032. The report segments the market by vaccine type, application, process and region. Competitive participants include Lonza Group, Catalent, Inc., Merck KGaA, Samsung...
Deutsch
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek